Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Fluoropyrimidines (5-fluorouracil, capecitabine) are the mainstay chemotherapeutic agents for the treatment of many types of cancer. Metabolism of fluoropyrimidines requires dihydropyrimidine dehydrogenase (DPD encoded by the DPYD gene) and reduced or absent activity of this enzyme can result in sev...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin Pharmacol Ther
Autors principals: Amstutz, Ursula, Henricks, Linda M., Offer, Steven M., Barbarino, Julia, Schellens, Jan H.M., Swen, Jesse J., Klein, Teri E., McLeod, Howard L., Caudle, Kelly E., Diasio, Robert B., Schwab, Matthias
Format: Artigo
Idioma:Inglês
Publicat: 2017
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5760397/
https://ncbi.nlm.nih.gov/pubmed/29152729
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.911
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars